Stimulation of nitric oxide-sensitive soluble guanylate cyclase in monocrotaline-induced pulmonary hypertensive rats
Authors:
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 203, 203-209
Abstract
No abstract availableKeywords
Funding Information
- grants-in-aid for scientific research program (15K08252)
This publication has 40 references indexed in Scilit:
- Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial HypertensionPLOS ONE, 2012
- Sildenafil Prevents and Reverses Transverse-Tubule Remodeling and Ca 2+ Handling Dysfunction in Right Ventricle Failure Induced by Pulmonary Artery HypertensionHypertension, 2012
- Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: A potential role for atrogin-1 in smooth muscleVascular Pharmacology, 2012
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60–2770, are not dependent on endogenous nitric oxide or reduced hemeAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- KMUP-1 ameliorates monocrotaline-induced pulmonary arterial hypertension through the modulation of Ca2+ sensitization and K+-channelLife Sciences, 2010
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Prolonged Inhaled NO Attenuates Hypoxic, but Not Monocrotaline-Induced, Pulmonary Vascular Remodeling in RatsAnesthesia & Analgesia, 1998
- Mechanistic imbalance of pulmonary vasomotor control in progressive lung injurySurgery, 1996
- Effects of Chronic Norepinephrine Administration on Cardiac Function in RatsJournal of Cardiovascular Pharmacology, 1995